Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone

被引：0
|
作者：
Mathews, Maju [1 ]
Pei, Huiling [1 ]
Savitz, Adam [1 ]
Nuamah, Isaac [1 ]
Elefant, Erica [1 ]
Hough, David [1 ]
Alphs, Larry [1 ]
Gopal, Srihari [1 ]
机构：
[1] Janssen Res & Dev, Titusville, NJ USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PM409
引用
收藏
页码：197 / 198
页数：2
相关论文
共 50 条
  • [1] Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis
    Mathews, Maju
    Pei, Huiling
    Savitz, Adam
    Nuamah, Isaac
    Hough, David
    Alphs, Larry
    Gopal, Srihari
    CLINICAL DRUG INVESTIGATION, 2018, 38 (08) : 695 - 702
  • [2] Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis
    Maju Mathews
    Huiling Pei
    Adam Savitz
    Isaac Nuamah
    David Hough
    Larry Alphs
    Srihari Gopal
    Clinical Drug Investigation, 2018, 38 : 695 - 702
  • [3] Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
    Corbeil, Olivier
    Essiambre, Anne-Marie
    Bechard, Laurent
    Roy, Audrey-Anne
    Huot-Lavoie, Maxime
    Brodeur, Sebastien
    Chandrasena, Ranjith
    Theriault, Chantale
    Crocker, Candice
    Melun, Jean-Pierre
    Tibbo, Phil
    Demers, Marie-France
    Roy, Marc-Andre
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2022, 12
  • [4] Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate
    Lencer, Rebekka
    Paz Garcia-Portilla, Maria
    Bergmans, Paul
    Gopal, Srihari
    Mathews, Maju
    Wooller, Annette
    Pungor, Katalin
    COMPREHENSIVE PSYCHIATRY, 2021, 107
  • [5] Symptomatic Remission and Functional Recovery after Paliperidone Palmitate 3-monthly or 1-monthly treatment in Asian Patients with Exacerbated Schizophrenia
    Savitz, Adam
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Hough, David
    Mathews, Maju
    Feng, Yu
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 242 - 243
  • [6] Low doses of palmitate of paliperidone 1-monthly (paliperidone palmitate 1-monthly): Results of real clinical practice
    Campos, J. A.
    Docasar, L.
    Seoane, A. M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S405 - S405
  • [7] Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophrenia
    Mathews, Maju
    Nuamah, Isaac
    Savitz, Adam
    Hough, David
    Najarian, Dean
    Kim, Edward
    Gopal, Srihari
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 198 - 198
  • [8] Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophrenia
    Mathews, Maju
    Nuamah, Isaac
    Savitz, Adam
    Hough, David
    Najarian, Dean
    Kim, Edward
    Gopal, Srihari
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 352S - 353S
  • [9] A stitch in time: 3-monthly long-acting injectable paliperidone palmitate in schizophrenia
    Taylor, Mark
    Huang, Hannah Chu-Han
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2017, 7 (10) : 231 - 233
  • [10] Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia
    Lamb, Yvette N.
    Keating, Gillian M.
    DRUGS, 2016, 76 (16) : 1559 - 1566
12345